Roy Freeman's most recent trade in Inhibikase Therapeutics Inc was a trade of 22,640 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 22,640 | 22,640 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Jan 2025 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Jan 2025 | 21,854 | 0 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 21,854 | 21,854 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Jan 2025 | 6,667 | 0 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Jan 2025 | 6,667 | 0 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 6,667 | 6,667 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 6,667 | 6,667 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Jan 2025 | 3,780 | 0 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 3,780 | 3,780 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Jan 2025 | 1,138 | 0 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 1,138 | 1,138 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 344,452 | 344,452 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 316,647 | 316,647 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 172,191 | 172,191 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 6,667 | 6,667 | - | - | Stock Option (right to buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 22,677 | 22,677 | - | - | Stock Option (right to buy) | |
| Inhibikase Therapeutics Inc | Roy Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2020 | 6,825 | 6,825 | - | - | Stock Option (right to buy) |